How Long Can You Stay on Wegovy?
Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with obesity or overweight plus weight-related conditions, and in kids 12+ with obesity. It's designed for long-term use, with no fixed duration limit—patients can stay on it indefinitely if they continue to benefit and tolerate it well.[1][2]
Clinical trials show sustained use: In the STEP 1 trial, participants on Wegovy lost 15-17% body weight over 68 weeks, with benefits maintained through 104 weeks in extensions. Real-world data supports ongoing use beyond 2 years for weight maintenance.[3][4]
When Do Doctors Stop Wegovy?
Treatment stops if weight loss plateaus without further benefit, side effects become intolerable, or risks outweigh gains—like in pregnancy (discontinue 2 months before planning). Guidelines recommend reassessing every 3-6 months; Novo Nordisk advises lifelong use for many to prevent regain, as 2/3 of weight returns within a year off GLP-1s.[2][5]
What Happens If You Stop Taking Wegovy?
Most patients regain about 2/3 of lost weight within 12 months, per STEP trials. Muscle loss or slowed metabolism from rapid weight drop can worsen rebound. Tapering isn't required, but some doctors suggest gradual dose reduction to ease GI symptoms.[3][6]
How Does Wegovy Dosing Work Long-Term?
Start at 0.25 mg weekly, titrate to 2.4 mg over 16 weeks. Maintenance stays at 2.4 mg indefinitely. No max duration, but supply shortages have forced pauses; check NovoCare for access.[2][7]
Wegovy vs. Ozempic or Zepbound for Long-Term Use
| Drug | Active Ingredient | Max Dose | Trial Duration Shown | Weight Regain Off-Drug |
|------|-------------------|----------|----------------------|-----------------------|
| Wegovy | Semaglutide | 2.4 mg/wk | Up to 4 years | ~67% in 1 year [3] |
| Ozempic | Semaglutide | 2.0 mg/wk (off-label weight use) | Up to 2 years | Similar to Wegovy [8] |
| Zepbound | Tirzepatide | 15 mg/wk | Up to 2 years | ~57% in 1 year [9] |
All are for chronic use; dual-agonist Zepbound shows slightly less regain but higher nausea risk.
Common Long-Term Side Effects and Risks
GI issues (nausea, diarrhea) hit 40-50% initially but drop over time. Rare risks include pancreatitis, gallbladder issues, or thyroid tumors (boxed warning). Long-term data beyond 4 years is limited; monitor thyroid, kidneys.[1][10] Patients report fatigue or hair loss with prolonged use.
Cost and Access for Ongoing Use
$1,300+/month without insurance. NovoCare coupons cap at $25/month for eligible. Patents protect until ~2032 in US; generics unlikely soon.[11][12]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/215256s007lbl.pdf
[2] Novo Nordisk Prescribing Info: https://www.wegovy.com
[3] NEJM STEP 1: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[4] STEP 5 Extension: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[5] JAMA Weight Regain Study: https://jamanetwork.com/journals/jama/fullarticle/2812936
[6] Wilding et al., Lancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00264-3/fulltext
[7] NovoCare: https://www.novocare.com
[8] Ozempic Label: https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/209637s020lbl.pdf
[9] SURMOUNT-1: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[10] FDA Warnings: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/semaglutide-marketed-ozempic-and-wegovy
[11] GoodRx Pricing: https://www.goodrx.com/wegovy
[12] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/WEGOVY